Harmony Biosciences Holdings, Inc. (HRMY)
42.60
-0.26
(-0.61%)
USD |
NASDAQ |
Sep 03, 11:18
Harmony Biosciences Holdings Cash from Investing (Quarterly) : -131.50M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -131.50M |
| March 31, 2026 | -183.65M |
| December 31, 2025 | -17.63M |
| September 30, 2025 | -4.789M |
| June 30, 2025 | -19.59M |
| March 31, 2025 | 2.362M |
| December 31, 2024 | -7.187M |
| September 30, 2024 | 0.745M |
| June 30, 2024 | -54.86M |
| March 31, 2024 | -6.186M |
| December 31, 2023 | -36.06M |
| September 30, 2023 | -0.813M |
| June 30, 2023 | -7.771M |
| March 31, 2023 | -1.79M |
| December 31, 2022 | -46.90M |
| Date | Value |
|---|---|
| September 30, 2022 | -32.44M |
| June 30, 2022 | -22.45M |
| March 31, 2022 | -40.04M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | -0.093M |
| June 30, 2021 | -0.201M |
| March 31, 2021 | -100.00M |
| December 31, 2020 | -2.00M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | -0.002M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | -77.04M |
| September 30, 2019 | -0.03M |
| June 30, 2019 | -0.051M |
| March 31, 2019 | -50.03M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Liquidia Corp. | -12.24M |
| Repligen Corp. | -2.089M |
| Johnson & Johnson | -1.11B |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| ANI Pharmaceuticals, Inc. | -3.054M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 92.43M |
| Cash from Financing (Quarterly) | -0.558M |
| Free Cash Flow | 335.65M |
| Free Cash Flow Per Share (Quarterly) | 1.573 |
| Free Cash Flow to Equity (Quarterly) | 77.98M |
| Free Cash Flow to Firm (Quarterly) | 94.92M |
| Free Cash Flow Yield | 13.41% |